

HAEMONETICS CORP
Form 8-K
January 28, 2011

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 26, 2011

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

(State or other jurisdiction
of incorporation)

1-14041

(Commission
File Number)

04-2882273

(I.R.S. Employer
Identification No.)

400 Wood Road

(Address of principal executive offices)

02184

(Zip Code)

Registrant's telephone number, including area code **781-848-7100**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 7.01 Regulation FD Disclosure.

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

Ex-99.1

Table of Contents

Item 5.02(c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 26, 2011, Haemonetics Corporation announced that the Board of Directors elected Paul M. Black to join its Board effective immediately. Mr. Black will serve on the Board's Audit and Compensation Committees, also effective immediately.

Mr. Black will receive the standard retainers and meeting fees payable to non-employee directors of the company, as described in the company's Proxy Statement dated June 17, 2010. Also pursuant to these arrangements, Mr. Black will receive equity compensation valued at \$200,000, half of which is granted as 6,002 shares in non-qualified stock options and half as 1,691 shares of restricted stock units. These shares will vest on the one year anniversary of the grant date.

Item 7.01 Regulation FD Disclosure.

The company's press release announcing the election of Mr. Black is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated January 26, 2011 announcing the election of Paul M. Black to join Haemonetics Board of Directors.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION
(Registrant)

Date: January 26, 2011

/s/ Susan Hanlon
Susan Hanlon, VP Finance

Table of Contents

EXHIBIT INDEX

- 99.1 Press Release issued by Haemonetics Corporation on January 26, 2011 announcing the election of Paul M. Black to join Haemonetics Board of Directors.